ADCTHealthcare · Drug Manufacturers - Specialty & GenericThe 5 Wall Street analysts covering ADC Therapeutics SA hold a median 12-month price target of $3 — +180.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 12 Sept 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores ADC Therapeutics SA on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (92): Sales and profits are climbing, and climbing faster than before.
Momentum (12): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ADCT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +180.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Aug 2026 | Guggenheim | Maintains | Buy | $10 → $5.00 |
| 8 June 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 8 June 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 4 June 2026 | RBC Capital | Downgrade | Sector Perform | — |
| 4 June 2026 | RBC Capital | Downgrade | Sector Perform | $6.00 → $2.00 |
| 5 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 May 2026 | RBC Capital | Reiterates | Outperform | — |
| 23 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Aug 2025 | Guggenheim | Reiterates | Buy | — |
| 20 June 2025 | RBC Capital | Maintains | Outperform | — |
| 13 June 2025 | Guggenheim | Maintains | Buy | — |
| 15 May 2025 | RBC Capital | Reiterates | Outperform | — |
| 31 Mar 2025 | Guggenheim | Maintains | Buy | — |
| 31 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Mar 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 24 Feb 2025 | Stephens & Co. | Maintains | Overweight | — |
| 6 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Dec 2024 | Guggenheim | Reiterates | Buy | — |
| 11 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ADCT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, ADC Therapeutics SA returned −67.9% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 82% of US stocks
Cheaper than 57% of US stocks
Cheaper than 94% of US stocks
Cheaper than 77% of US stocks
Higher than 32% of US stocks
Higher than 39% of US stocks
Higher than 95% of US stocks
Higher than 13% of US stocks
Higher than 5% of US stocks
Higher than 95% of US stocks
Higher than 20% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
ADC Therapeutics SA has a market value of $136.6M and an enterprise value of $355.7M.
Revenue in the twelve months to 30 June 2026: $79.6M. The latest quarter grew 2.2% year on year.
Net income over the same four quarters: −$96.9M, a −121.8% net margin.
Diluted earnings per share, trailing twelve months: $−0.66.
Free cash flow in the twelve months to 30 June 2026: −$102.3M.
Trailing P/E: −0.9×; forward P/E: −0.7× — the forward figure prices analyst consensus estimates, not reported earnings.
ADC Therapeutics SA employs 188 people — $423K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own ADC Therapeutics SA — and when they’d sell — is the membership. See the Ticker Nerd 20 →
ADC Therapeutics SA announced that its Chief Executive Officer, Ameet Mallik, will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York on September 11, 2026, at 9:10 a.m.
Why it matters — A fireside chat at a major healthcare conference gives investors an opportunity to hear directly from ADCT leadership about the company's outlook.
ADC Therapeutics reported second-quarter 2026 net product revenue of $18.6 million for ZYNLONTA, up from $18.1 million in the prior-year period, with management saying the treatment's commercial performance remained broadly consistent with recent quarters during the Q2 earnings call.
Why it matters — The quarter-over-quarter growth and management's assessment of ZYNLONTA's commercial performance provide a point of reference for investors tracking ADC Therapeutics' revenue trajectory.
ADC Therapeutics SA held its Q2 2026 earnings call, with the transcript published by Seeking Alpha. The call covered the company's financial results and operational updates for the quarter.
Why it matters — Earnings calls provide ADCT watchers with direct management commentary on the company's financial performance and strategic direction.
ADC Therapeutics reported a Q2 loss of $0.11 per share, narrower than the Zacks Consensus Estimate of a $0.19 loss and improved from the $0.50 per-share loss a year earlier. Revenue lagged consensus estimates for the quarter.
Why it matters — The narrower-than-expected quarterly loss marks an improvement from the prior year, though the revenue shortfall signals ADCT still faces demand headwinds.
ADC Therapeutics reported second quarter 2026 financial results with $18.6 million in net product revenue and $219.1 million in cash. The company also provided operational updates, including data submissions for ASH and a regulatory evaluation for ZYNLONTA® to pursue full approval and earlier-line DLBCL treatment.
Why it matters — ADCT watchers would care because the company is advancing ZYNLONTA® toward full approval and earlier lines of treatment for DLBCL, which could significantly expand its commercial opportunity.
The 5 Wall Street analysts covering ADC Therapeutics SA have a median 12-month price target of $3, with estimates ranging from $2 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering ADC Therapeutics SA, 3 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ADC Therapeutics SA 74 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, ADC Therapeutics SA ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (92 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +180.4% from the last close, and Ticker Nerd's factor model ranks ADC Therapeutics SA 74 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering ADC Therapeutics SA publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ADCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $5 over the next 12 months.
ADC Therapeutics SA returned -67.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
ADC Therapeutics SA is a Switzerland-based biotechnology company focused on developing and commercializing targeted antibody-drug conjugates for cancer treatment. Its portfolio centers on oncology programs designed to address hematological malignancies and solid tumors, with a particular emphasis on precision therapies that link monoclonal antibodies to potent cytotoxic agents.
The most recent item we track (PRNewsWire, 3 Sept 2026): "ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference". ADC Therapeutics SA announced that its Chief Executive Officer, Ameet Mallik, will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York on September 11, 2026, at 9:10 a.m.
ADC Therapeutics SA is a Switzerland-based biotechnology company focused on developing and commercializing targeted antibody-drug conjugates for cancer treatment. Its portfolio centers on oncology programs designed to address hematological malignancies and solid tumors, with a particular emphasis on precision therapies that link monoclonal antibodies to potent cytotoxic agents. The company’s current products and pipeline include ZYNLONTA and several investigational candidates such as loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. ADC Therapeutics SA operates in the specialty biopharmaceutical market, where antibody-drug conjugates are used to improve tumor targeting and expand treatment options for difficult-to-treat cancers. Headquartered in Epalinges, Switzerland, the company serves a global healthcare setting through research, development, and commercialization activities centered on next-generation oncology medicines.
CEO Dr. Ameet Mallik M.B.A., M.S. · 188 employees · Switzerland · https://www.adctherapeutics.com
